207 related articles for article (PubMed ID: 24218269)
41. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
[TBL] [Abstract][Full Text] [Related]
42. Novel roles for murine complement receptors type 1 and 2 II. Expression and function of CR1/2 on murine mesenteric lymph node T cells.
Molnár E; Prechl J; Erdei A
Immunol Lett; 2008 Mar; 116(2):163-7. PubMed ID: 18255161
[TBL] [Abstract][Full Text] [Related]
43. Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3.
Vik DP; Fearon DT
J Immunol; 1985 Apr; 134(4):2571-9. PubMed ID: 3156185
[TBL] [Abstract][Full Text] [Related]
44. The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.
Fridkis-Hareli M; Storek M; Or E; Altman R; Katti S; Sun F; Peng T; Hunter J; Johnson K; Wang Y; Lundberg AS; Mehta G; Banda NK; Michael Holers V
Mol Immunol; 2019 Jan; 105():150-164. PubMed ID: 30513451
[TBL] [Abstract][Full Text] [Related]
45. Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement.
Weis JJ; Fearon DT; Klickstein LB; Wong WW; Richards SA; de Bruyn Kops A; Smith JA; Weis JH
Proc Natl Acad Sci U S A; 1986 Aug; 83(15):5639-43. PubMed ID: 3016712
[TBL] [Abstract][Full Text] [Related]
46. Lack of induced co-stimulation as a result of complement receptor 2 (CR2) ligation on mouse splenic B cells.
Brown SL; Barrault DV; Phythian-Adams A; Knight AM
Int Immunol; 2006 Jan; 18(1):69-78. PubMed ID: 16291653
[TBL] [Abstract][Full Text] [Related]
47. Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor.
Kinoshita T; Thyphronitis G; Tsokos GC; Finkelman FD; Hong K; Sakai H; Inoue K
Int Immunol; 1990; 2(7):651-9. PubMed ID: 1703784
[TBL] [Abstract][Full Text] [Related]
48. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.
Nielsen CH; Marquart HV; Prodinger WM; Leslie RG
Immunology; 2001 Dec; 104(4):418-22. PubMed ID: 11899427
[TBL] [Abstract][Full Text] [Related]
49. CD21/CD35 in B cell activation.
Carroll MC
Semin Immunol; 1998 Aug; 10(4):279-86. PubMed ID: 9695184
[TBL] [Abstract][Full Text] [Related]
50. Expression of CR1 and CR2 complement receptors following Epstein-Barr virus infection of Burkitt's lymphoma cell lines.
Cohen JH; Fischer E; Kazatchkine MD; Lenoir GM; Lefevre-Delvincourt C; Revillard JP
Scand J Immunol; 1987 Jun; 25(6):587-98. PubMed ID: 3037684
[TBL] [Abstract][Full Text] [Related]
51. B cell-mediated antigen transport to splenic follicles.
Henningsson F; Ding Z; Heyman B
Scand J Immunol; 2014 Jan; 79(1):73-4. PubMed ID: 24219500
[No Abstract] [Full Text] [Related]
52. Complement receptors 1 and 2 in murine antibody responses to IgM-complexed and uncomplexed sheep erythrocytes.
Rutemark C; Bergman A; Getahun A; Hallgren J; Henningsson F; Heyman B
PLoS One; 2012; 7(7):e41968. PubMed ID: 22848677
[TBL] [Abstract][Full Text] [Related]
53. Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells.
Hivroz C; Fischer E; Kazatchkine MD; Grillot-Courvalin C
J Immunol; 1991 Mar; 146(6):1766-72. PubMed ID: 1826011
[TBL] [Abstract][Full Text] [Related]
54. A comparative study of normal B cells and the EBV-positive Burkitt's lymphoma cell line, Raji, as activators of the complement system.
Marquart HV; Olesen EH; Johnson AA; Damgaard G; Leslie RG
Scand J Immunol; 1997 Sep; 46(3):246-53. PubMed ID: 9315112
[TBL] [Abstract][Full Text] [Related]
55. B-cell extrinsic CR1/CR2 promotes natural antibody production and tolerance induction of anti-alphaGAL-producing B-1 cells.
Shimizu I; Kawahara T; Haspot F; Bardwell PD; Carroll MC; Sykes M
Blood; 2007 Feb; 109(4):1773-81. PubMed ID: 17023586
[TBL] [Abstract][Full Text] [Related]
56. Characterization of rat complement receptors and regulatory proteins. CR2 and Crry are conserved, and the C3b receptor of neutrophils and platelets is distinct from CR1.
Quigg RJ; Holers VM
J Immunol; 1995 Aug; 155(3):1481-8. PubMed ID: 7636211
[TBL] [Abstract][Full Text] [Related]
57. Analyses of the in vivo trafficking of stoichiometric doses of an anti-complement receptor 1/2 monoclonal antibody infused intravenously in mice.
Whipple EC; Shanahan RS; Ditto AH; Taylor RP; Lindorfer MA
J Immunol; 2004 Aug; 173(4):2297-306. PubMed ID: 15294942
[TBL] [Abstract][Full Text] [Related]
58. Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.
Seya T; Okada M; Hara T; Matsumoto M; Miyagawa S; Oshimura M
Immunology; 1991 Dec; 74(4):719-24. PubMed ID: 1723716
[TBL] [Abstract][Full Text] [Related]
59. The functional state of follicular dendritic cells in severe combined immunodeficient (SCID) mice: role of the lymphocytes.
Yoshida K; van den Berg TK; Dijkstra CD
Eur J Immunol; 1994 Feb; 24(2):464-8. PubMed ID: 8299696
[TBL] [Abstract][Full Text] [Related]
60. Two functionally different follicular dendritic cells in secondary lymphoid follicles of mouse spleen, as revealed by CR1/2 and FcR gamma II-mediated immune-complex trapping.
Yoshida K; van den Berg TK; Dijkstra CD
Immunology; 1993 Sep; 80(1):34-9. PubMed ID: 8244461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
